ClinicalTrials.gg
CompletedNCT03381703Updated Dec 22, 2017

Investigation of the Absorption, Metabolism, and Excretion and the Absolute Bioavailability of YH12852

A Phase 1 interventional study of YH12852 and 14C-labeled YH12852 in Constipation, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-22.

Sponsored by Seoul National University Hospital · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Mar 2017, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 23 studies in Constipation with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Constipation · Korea, Republic of.

Enrollment
20th of 20
10 · median 80
Started
2017
the only one that year
Phase 1
2 of 23
1 open now
Registered
16th of 23
by date
Lead sponsor
2 of 23
Seoul National University Hospital

Among the 23 studies in Constipation with a site in Korea, Republic of, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2017, is one of 2 in phase 1, and was the 16th registered.

Constipation

1,048 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

2 of the 23 studies in Constipation with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Constipation with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study investigates the absorption, metabolism, and excretion and the absolute bioavailability of YH12852 in healthy male subjects

Read the detailed description

Part 1 : Investigate the absorption metabolism, and excretion of YH12852 after single oral administration of YH12852 and 14C-labeled YH12852.

Part 2

: Investigate the absolute bioavailability of YH12852 after single oral administration of YH12852 followed by a single i.v. administration of 14C-labeled YH12852.

03

Conditions studied

  • Constipation

Browse trials for

Keywords

  • Accelerated Mass Spectrometry
  • Microtracer
  • Microdose
  • hAME
  • Absolute bioavailability
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who agreed to voluntarily participate in this study and comply with all the study requirements by signing form after being informed of the nature of this study and understanding all aspects of this study
  • Healthy adult, 19 - 55 of age (inclusive)
  • Subjects weighing over 55 kg (inclusive) with between 18 and 25 (inclusive) at screening visit
  • Subjects with no abnormal findings as determined by physical examination, , medical history, or clinical laboratory test results

Exclusion criteria

Exclusion Criteria:

  • History of gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorder
  • Surgery of the gastrointestinal tract that could interfere with kinetics of the study drug
  • History of (or suspected at screening visit) disease listed below Myocardial infarction Cerebral infarction/Stroke Arrythmia that need medical treatment Unstable angina Pulmonary hypertension
  • Subjects who are positive for , , and
  • History of relevant allergy/
  • Subjects who took prescribed medications within 14 days or over-the-counter (OTC) medications within 7 days prior to the first dose of the study drug
  • Subjects who have been consuming over 21 unit(1 unit = 10 g of alcohol) per week of alcohol prior to the study initiation or who is not able to stop consuming alcohol throughout the hospitalization period
  • Subjects who consumed products listed below within 2 days prior to the first dose of the study drug or who is not able to stop consuming products listed below until the last site visit Foods and/or beverages containing grapefruit Products containing caffeine (Coffee, tea, chocolate, caffeine-containing soft drinks)
  • Subject who is not willing to use throughout the study
  • Subjects who have smoked over 10 cigarettes until 3 months prior to the study initiation or who is not able to stop smoking throughout the hospitalization period
  • Subjects who have donated whole blood within 2 months or blood component within 1 month or received blood transfusion within 1 month of participating in this study
  • Administration of any products within 3 months from the first dose of the study drug
  • Subject who's serum prolactin is over 3-fold higher than the
  • Subject who judged not eligible for study participation by investigator
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Part 1

    Investigate the absorption, metabolism, and excretion of YH12852

    Drug: YH12852 · Drug: 14C-labeled YH12852

  • Experimental
    Part 2

    Investigate the absolute bioavailability of YH12852

    Drug: YH12852 · Drug: 14C-labeled YH12852

Interventions

  • YH12852 administration

  • Drug14C-labeled YH12852

    14C-labeled YH12852 administration

06

What researchers measure

Primary outcomes

  1. Total radioactivity

    Total radioactivity recovered

    Time frame: 0 - 288 hours (post-dose)

  2. Cmax of YH12852

    Peak concentration of YH12852

    Time frame: 0(pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288 hours (post-dose)

  3. AUClast of YH12852

    Area under the concentration-time curve from time 0 to the last measurable time of YH12852

    Time frame: 0(pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288 hours (post-dose)

  4. Fpo of YH12852

    Oral bioavailability of YH12852

    Time frame: 0(pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288 hours (post-dose)

Secondary outcomes

  1. Aef of YH12852

    Amount excreted in feces of YH12852

    Time frame: 0 - 288 hours (post-dose)

  2. Aeu of YH12852

    Amount excreted in urine of YH12852

    Time frame: 0 - 288 hours (post-dose)

07

Study locations

1 site
  • Seoul National University Hospital Clinical Trial Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Mar 2017, 0 months.

Of 13 phase 1 interventional studies under Constipation, half reached primary completion within 21 months of starting (the median); a quarter within 10 and three quarters within 38. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2017
First posted
Dec 22, 2017
StartActual
Mar 16, 2017
Primary completionActual
Mar 29, 2017
CompletionActual
Mar 29, 2017
Last update
Dec 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03381703
Responsible party
Sponsor
First posted
Dec 22, 2017
Start date
Mar 16, 2017
Primary completion
Mar 29, 2017
Completion
Mar 29, 2017
Last update
Dec 22, 2017

Study contacts

Howard Lee, MD., PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YH12852

Start the discussion